As AAOS Sees Record Growth in Fracture & Trauma Registry Data Submissions, Technology Partnership Offering with PatientIQ Expands to Include Nationwide Participation Options

On the heels of a successful technology pilot program with PatientIQ, the American Academy of Orthopaedic Surgeons (AAOS) has seen a rapid increase in data submissions to the Fracture & Trauma Registry (FTR). Through the submission and analysis of data to the FTR, healthcare systems and orthopaedic surgeons can actively utilize the knowledge gained to improve outcomes and the quality of orthopaedic care in turn supporting highly informed decision-making and quality improvement.

AAOS partnered with PatientIQ in December 2022 to integrate its cloud-based platform directly with FTR participants’ electronic health records (EHR) and simplify the process to collect and submit registry data for five of the more common fractures in the U.S. Within the first eight months, the partnership yielded a substantial increase in data submitted to the FTR. By expanding the participation options to include the PatientIQ solution, the FTR is reducing barriers to tracking evidence-based practices and advancing the delivery of musculoskeletal care. To date, there are 35 participating sites contributing to the FTR.

Michael J. Gardner, MD, FAAOS,
chair of the AAOS Fracture & Trauma Registry Steering Committee
….

“Due to the complexity of having five modules in one registry, we recognized potential data challenges for some sites. We collaborated with PatientIQ to help mitigate the burden and enhance data submission.Consequently, data within the registry has increased significantly and is helping fuel new momentum within the registry.”

Automating Registry Participation Within a Matter of Weeks
Utilizing FHIR-based APIs and other live integration functionality, PatientIQ can help extract and translate critical health information into registry-compliant specifications and submit it on behalf of participating orthopaedic surgeons. In doing so, the platform eases the administrative and technological burden associated with submitting procedural, post operative and patient-reported outcomes to the FTR.

Click here to watch a webinar discussing one customer’s journey with the FTR Powered by PatientIQ.

Hospital sites, ambulatory service centers or institutions where fracture and trauma-related incidents are treated are invited to participate in the FTR. Enrollment through PatientIQ is encouraged, but optional. To get involved with the FTR, email an AAOS Registry engagement associate at RegistryEngagement@aaos.org, call 847-292-0530, or click here. For more information about PatientIQ, visit www.patientiq.io.

SourceAAOS
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy